Company Description
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.
The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient’s infection.
It offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment.
The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers.
The company has a collaboration the initiation of Genomic Prostate Score (GPS) testing. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010.
MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Country | Belgium |
| Founded | 2003 |
| IPO Date | Nov 4, 2021 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 364 |
| CEO | Michael McGarrity |
Contact Details
Address: CAP Business Center, Rue d’Abhooz 31 Herstal, 4040 Belgium | |
| Phone | 866 259 5644 |
| Website | mdxhealth.com |
Stock Details
| Ticker Symbol | MDXH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $13.46 |
| CIK Code | 1872529 |
| CUSIP Number | 58286E102 |
| ISIN Number | BE0974461940 |
| SIC Code | 8071 |
Key Executives
| Name | Position |
|---|---|
| Michael K. McGarrity | Chief Executive Officer and Executive Director |
| Ron Kalfus CPA | Interim Chief Financial Officer |
| Joseph Sollee J.D., LLM | Executive Vice President of Corporate Development and General Counsel |
| John A. Bellano | Chief Commercial Officer |
| Scott McMahan | Vice President of Finance and Accounting |
| Kim Leroux | Executive Vice President of Revenue Cycle Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2026 | 6-K | Report of foreign issuer |
| Apr 30, 2026 | 6-K | Report of foreign issuer |
| Apr 3, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 3, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Feb 26, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 11, 2026 | F-3/A | Filing |
| Feb 11, 2026 | 6-K | Report of foreign issuer |
| Jan 16, 2026 | SCHEDULE 13G/A | Filing |
| Jan 12, 2026 | 6-K | Report of foreign issuer |